Search





Search





Markets
/
Stocks
/
nasdaq-smmt
/

Summit Therapeutics Inc

SMMT

Add to Watchlist

16.870USD

-1.270-7.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

14.08BMarket Cap

LossP/E TTM



Summit Therapeutics Inc

16.870

-1.270-7.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Summit Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Summit Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.57.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Summit Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

101 / 382

Overall Ranking

225 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Summit Therapeutics Inc Highlights

StrengthsRisks

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -10.52, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 122.68M shares, increasing 3.43% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 96.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.47.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

29.571

Target Price

+57.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Summit Therapeutics Inc is 6.80, ranking 188 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.70

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Summit Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Summit Therapeutics Inc is 7.01, ranking 177 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -10.52, which is -373.12% below the recent high of 28.75 and -2767.50% above the recent low of -301.80.

Score

Industry at a Glance

Previous score

7.01

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Summit Therapeutics Inc is 7.53, ranking 292 out of 382 in the Biotechnology & Medical Research industry. The average price target is 34.50, with a high of 42.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

7.67

Change

-0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

29.571

Target Price

+63.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Summit Therapeutics Inc

SMMT

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Summit Therapeutics Inc is 6.95, ranking 121 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 25.69 and the support level at 11.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.11

Change

-0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.678

Sell

RSI(14)

39.832

Neutral

STOCH(KDJ)(9,3,3)

37.792

Sell

ATR(14)

1.513

High Vlolatility

CCI(14)

-62.800

Neutral

Williams %R

76.154

Sell

TRIX(12,20)

-0.555

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

18.282

Sell

MA10

17.901

Sell

MA20

20.061

Sell

MA50

18.787

Sell

MA100

17.588

Sell

MA200

19.249

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Summit Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 15.81%, representing a quarter-over-quarter increase of 11.68%. The largest institutional shareholder is PRFDX, holding a total of 9.26M shares, representing 1.19% of shares outstanding, with 37.27% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Duggan (Robert William)

570.07M

+2.51%

Baker Bros. Advisors LP

36.39M

+7.91%

Zanganeh (Mahkam)

35.74M

+1.02%

Xia (Yu)

31.52M

Fidelity Management & Research Company LLC

13.34M

+49.58%

T. Rowe Price Associates, Inc.

Star Investors

9.26M

+109.18%

State Street Investment Management (US)

6.64M

+4.31%

BlackRock Institutional Trust Company, N.A.

6.47M

+3.94%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Summit Therapeutics Inc is 5.08, ranking 54 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -1.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Summit Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.